嘉应制药获融资买入165.27万元，不久前被立案受损股民可索赔

Group 1 - The core viewpoint of the articles highlights that Jia Ying Pharmaceutical is currently under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact investor confidence and stock performance [2][3] - As of June 20, 2023, Jia Ying Pharmaceutical's financing balance is 248 million yuan, representing 8.17% of its market capitalization, which is below the historical 50th percentile level [2] - The company reported a significant decline in financial performance for 2024, with total operating revenue of 376 million yuan, down 29.46% year-on-year, and a net profit attributable to shareholders of 21 million yuan, down 39.94% year-on-year [3] Group 2 - Investors who purchased Jia Ying Pharmaceutical shares between its listing and May 28, 2025, and still held them at the close on that date, may be eligible for compensation due to the company's alleged information disclosure failures [3] - The company, established in 2003 and a member of the Sheneng Group, is primarily engaged in the pharmaceutical manufacturing industry, specifically in traditional Chinese medicine [3]